Your browser doesn't support javascript.
loading
Protopine/Gemcitabine Combination Induces Cytotoxic or Cytoprotective Effects in Cell Type-Specific and Dose-Dependent Manner on Human Cancer and Normal Cells.
Garcia-Gil, Mercedes; Turri, Benedetta; Gabriele, Morena; Pucci, Laura; Agnarelli, Alessandro; Lai, Michele; Freer, Giulia; Pistello, Mauro; Vignali, Robert; Batistoni, Renata; Marracci, Silvia.
Affiliation
  • Garcia-Gil M; Department of Biology, University of Pisa, 56127 Pisa, Italy.
  • Turri B; Interdepartmental Research Center "Nutraceuticals and Food for Health", University of Pisa, 56127 Pisa, Italy.
  • Gabriele M; Department of Biology, University of Pisa, 56127 Pisa, Italy.
  • Pucci L; Institute of Agricultural Biology and Biotechnology, National Research Council, 56124 Pisa, Italy.
  • Agnarelli A; Institute of Agricultural Biology and Biotechnology, National Research Council, 56124 Pisa, Italy.
  • Lai M; Department of Biology, University of Pisa, 56127 Pisa, Italy.
  • Freer G; Retrovirus Centre, Department of Translational Medicine and New Technologies in Medicine and Surgery, University of Pisa, 56127 Pisa, Italy.
  • Pistello M; Retrovirus Centre, Department of Translational Medicine and New Technologies in Medicine and Surgery, University of Pisa, 56127 Pisa, Italy.
  • Vignali R; Retrovirus Centre, Department of Translational Medicine and New Technologies in Medicine and Surgery, University of Pisa, 56127 Pisa, Italy.
  • Batistoni R; Department of Biology, University of Pisa, 56127 Pisa, Italy.
  • Marracci S; Department of Biology, University of Pisa, 56127 Pisa, Italy.
Pharmaceuticals (Basel) ; 14(2)2021 Jan 26.
Article de En | MEDLINE | ID: mdl-33530428
The natural alkaloid protopine (PRO) exhibits pharmacological properties including anticancer activity. We investigated the effects of PRO, alone and in combination with the chemotherapeutic gemcitabine (GEM), on human tumor cell lines and non-tumor human dermal fibroblasts (HDFs). We found that treatments with different PRO/GEM combinations were cytotoxic or cytoprotective, depending on concentration and cell type. PRO/GEM decreased viability in pancreatic cancer MIA PaCa-2 and PANC-1 cells, while it rescued the GEM-induced viability decline in HDFs and in tumor MCF-7 cells. Moreover, PRO/GEM decreased G1, S and G2/M phases, concomitantly with an increase of subG1 phase in MIA PaCa-2 and PANC-1 cells. Differently, PRO/GEM restored the normal progression of the cell cycle, altered by GEM, and decreased cell death in HDFs. PRO alone increased mitochondrial reactive oxygen species (ROS) in MIA PaCa-2, PANC-1 cells and HDFs, while PRO/GEM increased both intracellular and mitochondrial ROS in the three cell lines. These results indicate that specific combinations of PRO/GEM may be used to induce cytotoxic effects in pancreatic tumor MIA PaCa-2 and PANC-1 cells, but have cytoprotective or no effects in HDFs.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Pharmaceuticals (Basel) Année: 2021 Type de document: Article Pays d'affiliation: Italie Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Pharmaceuticals (Basel) Année: 2021 Type de document: Article Pays d'affiliation: Italie Pays de publication: Suisse